FOURTH AMENDMENT TO COLLABORATION AGREEMENT BETWEEN ONYX PHARMACEUTICALS, INC. AND BAYER CORPORATIONCollaboration Agreement • February 27th, 2012 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This Fourth Amendment to the Collaboration Agreement (the “Fourth Amendment”) is dated October 11, 2011 (the “Effective Date of the Fourth Amendment”) by and between ONYX PHARMACEUTICALS, Inc., a Delaware corporation having its principal place of business in South San Francisco, California (“Onyx”) and BAYER HEALTHCARE LLC, a Delaware company having its principal place of business in Tarrytown, New York, as successor-in-interest to BAYER CORPORATION (“Bayer”). Bayer and Onyx may be referred to herein individually as “Party,” or collectively, as the “Parties.”
AGREEMENT REGARDING REGORAFENIB between BAYER HEALTHCARE LLC and ONYX PHARMACEUTICALS, INC. Dated as of October 11, 2011Agreement Regarding Regorafenib • February 27th, 2012 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
This AGREEMENT REGARDING REGORAFENIB (this “Agreement”) is entered into as of this 11th day of October, 2011 (the “Effective Date”) between BAYER HEALTHCARE LLC, a Delaware limited liability company (“Bayer”) and ONYX PHARMACEUTICALS, INC., a Delaware corporation (“Onyx”). Bayer and Onyx are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO LEASELease • February 27th, 2012 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of November 1, 2011, by and between ARE-SAN FRANCISCO NO. 12, LLC, a Delaware limited liability company (“Landlord”), and ONYX PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
SETTLEMENT AGREEMENT AND RELEASESettlement Agreement and Release • February 27th, 2012 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
This Settlement Agreement and Release (“Settlement Agreement”) is entered into by and among Onyx Pharmaceuticals, Inc. (“Onyx”), a Delaware corporation, on the one hand, and Bayer Corporation, an Indiana corporation, Bayer AG, a German corporation, Bayer HealthCare LLC, a Delaware limited liability company, and Bayer Pharma AG, a German corporation and successor-in-interest to Bayer Schering Pharma AG, a German corporation (collectively, “Bayer”), on the other hand (Onyx and Bayer collectively referred to as the “Parties”). This Settlement Agreement shall be effective as of the date last executed by any Party (“Effective Date”).
LEASE AGREEMENTLease Agreement • February 27th, 2012 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS LEASE AGREEMENT (this “Lease”) is made this 1st day of November, 2011, between ARE-SAN FRANCISCO NO. 12, LLC, a Delaware limited liability company (“Landlord”), and ONYX PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
